EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors

Ariana P Vargas-Delgado iD, Estefania Arteaga Herrera, Cesar Tumbaco Mite iD, Patricia Delgado Cedeno, Maria Cristina Van Loon, Juan J Badimon iD

International Journal of Molecular Sciences · 18.02.2023 · 24 (4) · 4144

DOI: 10.3390/ijms24044144 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 18.02.2023. Verfasst von Ariana P Vargas-Delgado und 5 weiteren Autor:innen. Beteiligte Einrichtung: AtheroThrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Glycosuria. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sodium–glucose cotransporter type 2 inhibitors (SGLT2i) are glycosuric drugs that were originally developed for the treatment of type 2 diabetes mellitus (T2DM). There is a hypothesis that SGLT2i are drugs that are capable of increasing ketone bodies and free fatty acids. The idea is that they could serve as the necessary fuel, instead of glucose, for the purposes of cardiac muscle requirements and could explain antihypertensive effects, which are independent of renal function. The adult heart, under normal conditions, consumes around 60% to 90% of the cardiac energy that is derived from the oxidation of free fatty acids. In addition, a small proportion also comes from other available substrates. In order to meet energy demands with respect to achieving adequate cardiac function, the heart is known to possess metabolic flexibility. This allows it to switch between different available substrates in order to obtain the energy molecule adenosine triphosphate (ATP), thereby rendering it highly adaptive. It must be noted that oxidative phosphorylation in aerobic organisms is the main source of ATP, which is a result of reduced cofactors. These cofactors include nicotine adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2), which are the result of electron transfer and are used as the enzymatic cofactors that are involved in the respiratory chain. When there is an excessive increase in energy nutrients—such as glucose and fatty acids—which occur in the absence of a parallel increase in demand, a state of nutrient surplus (which is better known as an excess in supply) is created. The use of SGLT2i at the renal level has also been shown to generate beneficial metabolic alterations, which are obtained by reducing the glucotoxicity that is induced by glycosuria. Together with the reduction in perivisceral fat in various organs, such alterations also lead to the use of free fatty acids in the initial stages of the affected heart. Subsequently, this results in an increase in production with respect to ketoacids, which are a more available energy fuel at the cellular level. In addition, even though their mechanism is not fully understood, their vast benefits render them of incredible importance for the purposes of further research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2GlycosuriaHumansFatty Acids, NonesterifiedKidneyGlucoseKetone BodiesAdenosine Triphosphate

Stichwörter der Autor:innen

arterial stiffnesschronic kidney diseasefree fatty acidsheart failureketone bodiessodium–glucose cotransporter type 2 inhibitorstype 2 diabetes mellitus

Substanzen

Sodium-Glucose Transporter 2 InhibitorsFatty Acids, NonesterifiedGlucoseKetone BodiesAdenosine Triphosphate

Autor:innen und Institutionen

  • AtheroThrombosis Research Unit, Mount Sinai Heart, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY 10029, USA.
  • Instituto Ecuatoriano del Corazón (IECOR), Guayaquil 090513, Ecuador.

ORCID-Profile: Ariana P Vargas-Delgado, Cesar Tumbaco Mite, Juan J Badimon

Zitieren

APA

Vargas-Delgado, A. P., Arteaga Herrera, E., Tumbaco Mite, C., Delgado Cedeno, P., Van Loon, M. C., & Badimon, J. J. (2023). Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. International Journal of Molecular Sciences, 24(4), 4144. https://doi.org/10.3390/ijms24044144

Vancouver

Vargas-Delgado AP, Arteaga Herrera E, Tumbaco Mite C, Delgado Cedeno P, Van Loon MC, Badimon JJ. Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors. International Journal of Molecular Sciences. 2023;24(4):4144. doi:10.3390/ijms24044144

BibTeX
@article{VargasDelgado2023,
  author = {Vargas-Delgado, Ariana P and Arteaga Herrera, Estefania and Tumbaco Mite, Cesar and Delgado Cedeno, Patricia and Van Loon, Maria Cristina and Badimon, Juan J},
  title = {Renal and Cardiovascular Metabolic Impact Caused by Ketogenesis of the SGLT2 Inhibitors},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {4},
  pages = {4144},
  doi = {10.3390/ijms24044144}
}
Kostenlos starten →